Cover Page

Cite item


Acne (Ac) represents a widespread dermatosis most commonly found in adolescents and adults covering 6-85% total cases. It has been traditionally believed that Propionibacterium acnes (P. acnes) colonizes ducts of the sebaceous hair follicles (SHFs), activates innate immune response and triggers transition of non-inflammatory erosions (comedones) into inflammatory lesions such as papules, pustules and nodules. Moreover, it was also shown that inflammatory reaction develops at late Ac stage and its severe course. Today, it has been evidenced that Ac-coupled inflammation develops at all stages of dermatosis, perhaps in a subclinical manner, even prior to emergence of comedones.

It is commonly accepted that acne targets SHFs displaying location-related marked morphological, microbiological and metabolic diversity. For instance, SHFs is profoundly affected by altered hormone and immunological properties as well as environmental cues.

Comparative studies examining efficacy nd medicated therapy with anti-inflammatgory potential evidence about early inflammatory reaction related to acne.

The data obtained confirm that P. acnes elicits inflammatory reaction in acne that additionally maintains P. acnes proliferation. It was found that P. acnes initiates TLR2-mediated innate immune reaction both at early and late stages of developing dermatosis. Such reaction results in upregulated immune genes including those encoding cytokines and chemokines recruiting immune cells.

Today, owing to clinical, immunological, histology and immunohistochemistry data there has been accumulated evidence confirming significance of ongoing inflammation as a pathophysiological basis for emerging acne.

Upon that, pathophysiological mechanisms triggering inflammatory reaction in acne are complex and poorly investigated, thereby underlying a need to conduct further studies.

About the authors

A. G. Rumyantsev

D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Rumyantsev A.G., PhD, MD (Medicine), Professor, Full Member, Russian Academy of Scienes, President Russian Federation

O. M. Demina

D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Author for correspondence.

Demina Olga Michailovna, PhD (Medicine), Assosiate Professor, Head, Scientific and Organizational Department

Phone: 7 (910) 490-91-59

Russian Federation

E. V. Raikina

D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Raikina E.V., PhD (Medicine), Head, Laboratory of Molecular Biology Russian Federation


  1. Afshar M., Gallo R.L. Innate immune defense system of the skin. Vet. Dermatol., 2013, Vol. 24, pp. 32-38.
  2. Agier J., Brzezińska-Błaszczyk E. Cathelicidins and defensins regulate mast cell antimicrobial activity. Postepy Hig. Med. Dosw. (Online), 2016, Vol. 16, no. 70 (0), pp. 618-636.
  3. Alan M., O’Neill, Richard L.G. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome, 2018, Vol. 6, no. 1, 177. doi: 10.1186/s40168-018-0558-5.
  4. Antiga E., Verdelli A., Bonciani D., Bonciolini V., Caproni M., Fabbri P. Acne: a new model of immunemediated chronic inflammatory skin disease. G. Ital. Dermatol. Venereol., 2015, Vol. 150. no. 2, pp. 247-254.
  5. Beylot C., Auffret N., Poli F., Claudel J.P., Leccia M.T., Del Giudice P., Dreno B. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J. Eur. Acad. Dermatol. Venereol., 2014, Vol. 28, no. 3, pp. 271-278.
  6. Biton A., Ansorge S., Bank U., Täger M., Reinhold D., Brocke S. Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions. Immunobiology, 2011, Vol. 216, no. 12, pp. 1295-1301.
  7. Bojar R.A., Holland K.T. Acne and Propionibacterium acnes. Clin. Dermatol., 2004, Vol. 22, no. 5. pp. 375-379.
  8. Bruggemann H., Henne A., Hoster F. The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science, 2004, Vol. 305, pp. 671-673.
  9. Choi D.K., Li Z.J., Chang I.K. Regional difference of inflammatory acne lesions according to beta-defensin-2 expression. J. Invest. Dermatol., 2014, Vol. 134, pp. 2044-2046.
  10. Dessinioti C., Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin. Dermatol., 2017, Vol. 35, no. 2, pp. 163-167.
  11. Dréno B. What is new in the pathophysiology of acne, an overview. J. Eur. Acad. Dermatol. Venereol., 2017, Vol. 31, no. 5, pp. 8-12.
  12. Dreno B., Gollnick H.P., Kang S. Understanding innate immunity and inflammation in acne: implications for management. J. Eur. Acad. Dermatol. Venereol., 2015, Vol. 29, no. 4, pp. 3-11.
  13. Gollnick H., Abanmi A.A., Al-Enezi M., Al Hammadi A., Galadari I., Kibbi A.G., Zimmo S. Managing acne in the Middle East: consensus recommendations. J. Eur. Acad. Dermatol. Venereol., 2017, Vol. 31, no. 7, pp. 4-35.
  14. Gonzalez P., Vila R., Cirigliano M. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study. J. Cosmet. Dermatol., 2012, Vol. 11, no. 4, pp. 251-260.
  15. Grice E.A., Segre J.A. The skin microbiome. Nat. Rev. Microbiol., 2011, Vol. 9, pp. 244-253.
  16. Harvey A., Huynh T.T. Inflammation and acne: putting the pieces together. J. Drugs Dermatol., 2014, Vol. 13, no. 4, pp. 459-463.
  17. Huang Y.C., Yang C.H., Li T.T., Zouboulis C.C., Hsu H.C. Cell-free extracts of Propionibacterium acnes stimulate cytokine production through activation of p38 MAPK and Toll-like receptor in SZ95 sebocytes. Life Sci., 2015, Vol. 15, no. 139, pp. 123-131.
  18. Jasson F., Nagy I., Knol A.C., Zuliani T., Khammari A., Dréno B. Different strains of Propionibacterium acnes modulate differently the cutaneous innate immunity. Exp. Dermatol., 2013, Vol. 22, no. 9, pp. 587-592.
  19. Jeremy A.H., Holland D.B., Roberts S.G., Thomson K.F., Cunliffe W.J. Inflammatory events are involved in acne lesion initiation. J. Invest. Dermatol., 2003, Vol. 121, pp. 20-27.
  20. Jeremy A.H., Holland D.B., Roberts S.G., Thomson K.F., Cunliffe W.J., Jugeau S., Tenaud I., Knol A.C. Induction of toll-like receptors by Propionibacterium acnes. Br. J. Dermatol., 2005, Vol. 153, pp. 1105-1113.
  21. Kang S., Cho S., Chung J.H. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am. J. Pathol., 2005, Vol. 166, pp. 1691-1699.
  22. Kim J., Ochoa M.T., Krutzik S.R., Takeuchi O., Uematsu S., Legaspi A.J., Brightbill H.D., Holland D., Cunliffe W.J., Akira S., Sieling P.A., Godowski P.J., Modlin R.L. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol., 2002, Vol. 1, no. 169 (3), pp. 1535-1541.
  23. Kircik L.H. Harnessing the anti-inflammatory effects of topical dapsone for management of acne. J. Drugs Dermatol., 2010, Vol. 9, no. 6, pp. 667-671.
  24. Kistowska M., Meier B., Proust T. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. J. Invest. Dermatol., 2015, Vol. 135, pp. 110-118.
  25. Krause K., Schnitger A., Fimmel S., Glass E., Zouboulis C.C. Corticotropinreleasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm. Metab. Res., 2007, Vol. 39, pp. 166-170.
  26. Kupper T.S. Personal reflections on 25 years of immunodermatology. Br. J. Dermatol., 2014, Vol. 171, no. 4, pp. 684-686.
  27. Layton A.M., Morris C., Cunliffe W.J., Ingham E. Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Exp. Dermatol., 1998, Vol. 7, no. 4, pp. 191-197.
  28. Lee S.E., Kim J.M., Jeong S.K., Jeon J.E., Yoon H.J., Jeong M.K., Lee S.H. Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes. Arch. Dermatol. Res., 2010, Vol. 302, no. 10, pp. 745-756.
  29. Lee S.E., Kim J.M., Jeong S.K., Choi E.H., Zouboulis C.C., Lee S.H. Expression of protease-activated receptor-2 in SZ95 sebocytes and its role in sebaceous lipogenesis, inflammation, and innate immunity. J. Invest. Dermatol., 2015, Vol. 135, no. 9, pp. 2219-2227.
  30. Leeming J.P., Holland K.T., Cuncliffe W.J. The microbial colonization of inflamed acne vulgaris lesions. Br. J. Dermatol., 1988, Vol. 118, no. 2, pp. 203-208.
  31. McDowell A., Nagy I., Magyari M., Barnard E., Patrick S. The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLoS ONE, 2013, Vol. 8, no. 9, e70897. doi: 10.1371/journal.pone.0070897.
  32. Melnik B.C. Is sebocyte-derived leptin the missing link between hyperseborrhea, ductal hypoxia, inflammation and comedogenesis in acne vulgaris? Exp. Dermatol., 2016, Vol. 25, no. 3, pp. 181-182.
  33. Melnik B.C. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. Clin. Cosmet. Investig. Dermatol., 2015, Vol. 8, pp. 371-388.
  34. Nagy I., Pivarcsi A., Koreck A., Szell M., Urban E., Kemeny L. Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J. Invest. Dermatol., 2005, Vol. 12, pp. 931-938.
  35. Nakatsuji T., Kao M.C., Zhang L., Zouboulis C.C., Gallo R.L., Huang C.M. Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J. Invest. Dermatol., 2010, Vol. 130, no. 4, pp. 985-994.
  36. Nakatsuji T., Liu Y.T., Huang C.P., Zoubouis C.C., Gallo R.L., Huang C.M. Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J. Invest. Dermatol., 2008, Vol. 128, pp. 2451-2457.
  37. Nestle F.O., di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and disease. Nat. Rev. Immunol., 2009, Vol. 9, pp. 679-691.
  38. Norris J.F., Cunliffe W.J. A histological and immunocytochemical study of early acne lesions. Br. J. Dermatol., 1988, Vol. 118, no. 5, pp. 651-659.
  39. Pelle E., McCarthy J., Seltmann H. Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes. J. Invest. Dermatol., 2008, Vol. 128, pp. 1280-1285.
  40. Qin M., Landriscina A., Rosen J.M. Nitric oxide-releasing nanoparticles prevent Propionibacterium acnesinduced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response. J. Invest. Dermatol., 2015, Vol. 135, pp. 2723-2731.
  41. Saint-Jean M., Khammari A., Jasson F., Nguyen J.M., Dréno B.. Different cutaneous innate immunity profiles in acne patients with and without atrophic scars. Eur. J. Dermatol., 2016, Vol. 26, no. 1, pp. 68-74.
  42. Sanford J.A., Gallo R.L. Functions of the skin microbiota in health and disease. Semin. Immunol., 2013, Vol. 25, pp. 370-377.
  43. Seite S., Bieber T. Barrier function and microbiotic dysbiosis in atopic dermatitis. Clin. Cosmet. Investig. Dermatol., 2015, Vol. 8, pp. 479-483.
  44. Shaheen B., Gonzalez M. Acne sans P. acnes. J. Eur. Acad. Dermatol. Venereol., 2013, Vol. 27, no. 1, pp. 1-10.
  45. Shu M., Wang Y., Yu J. Fermentation of Propionibacterium acnes, a commensal bacterium in the human skin microbiome, as skin probiotics against methicillin-resistant Staphylococcus aureus. PLoS ONE, 2013, Vol. 8, no. 2, e55380. doi: 10.1371/journal.pone.0055380.
  46. Simonart T. Immunotherapy for acne vulgaris: current status and future directions. Am. J. Clin. Dermatol., 2013, Vol. 14, no. 6, pp. 429-435.
  47. Song M., Seo S.H., Ko H.C., Oh C.K., Kwon K.S., Chang C.L., Kim M.B. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea. J. Dermatol., 2011, Vol. 38, no. 7, pp. 667-673.
  48. Stein Gold L.F. What's new in acne and inflammation? J. Drugs Dermatol., 2013, Vol. 1, no. 12 (6), pp. 67-69.
  49. Tan J. Dapsone 5% gel: a new option in topical therapy for acne. Skin Therapy Lett., 2012, Vol. 17, no. 8, pp. 1-3.
  50. Tanghetti E., Abramovits W., Solomon B., Loven K., Shalita A. Tazarotene versus tazarotene plus clindamycin/ benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J. Drugs Dermatol., 2006, Vol. 5, no. 3, pp. 256-261.
  51. Tanghetti E., Dhawan S., Green L., Ling M., Downie J., Germain M.A., Kasteler J.S., Kircik L., Oefelein M.G., Draelos Z. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J. Drugs Dermatol., 2011, Vol. 10, no. 7, pp. 783-792.
  52. Thielitz A., Ansorge S., Bank U., Tager M., Wrenger S., Gollnick H., Reinhold D. The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. Front. Biosci., 2008, Vol. 13, pp. 2364-2375.
  53. Thielitz A., Reinhold D., Vetter R., Lendeckel U., Kähne T., Bank U., Helmuth M., Neubert K., Faust J., Hartig R., Wrenger S., Zouboulis C.C., Ansorge S., Gollnick H. Possible role of DP IV inhibitors in acne therapy. Adv. Exp. Med. Biol., 2006, Vol. 575, pp. 163-167.
  54. Tochio T., Tanaka H., Nakata S., Ikeno H. Accumulation of lipid peroxide in the content of comedones may be involved in the progression of comedogenesis and inflammatory changes in comedones. J. Gosmet. Dermatol., 2009, Vol. 8, pp. 152-158.
  55. Torocsik D., Kovacs D., Camera E. Leptin promotes a proinflammatory lipid profile and induces inflammatory pathways in human SZ95 sebocytes. Br. J. Dermatol., 2014, Vol. 171, pp. 1326-1335.
  56. Trivedi N.R., Cong Z., Nelson A.M. Peroxisome proliferator-activated receptors increase human sebum production. J. Invest. Dermatol., 2006, Vol. 126, pp. 2002-2009.
  57. Trivedi N.R., Gilliland K.L., Zhao W. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J. Invest. Dermatol., 2006, Vol. 126, pp. 1071- 1079.
  58. Trompezinski S., Weber S., Cadars B. Assessment of a new biological complex efficacy on dysseborrhea, inflammation, and Propionibacterium acnes proliferation. Clin. Cosmet. Investi. Dermatol., 2016, Vol. 9, pp. 233-239.
  59. Wiesner J., Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence, 2010, Vol. 1, pp. 440-464.
  60. Xia X., Li Z., Liu K., Wu Y., Jiang D., Lai Y. Staphylococcal LTA-induced miR-143 inhibits Propionibacterium acnes-mediated inflammatory response in skin. J. Invest. Dermatol., 2016, Vol. 136, pp. 621-630.
  61. Zhang L., Li W.H., Anthonavage M., Eisinger M. Melanocortin-5 receptor: a marker of human sebocyte differentiation. Peptides, 2006, Vol. 27, pp. 413-420.
  62. Zouboulis C.C. Sebaceous gland receptors. Dermatoendocrinology, 2009, Vol. 1, pp. 77-80.
  63. Zouboulis C.C. The sebaceous gland. Hautarzt, 2010, Vol. 61, no. 6, pp. 467-468.
  64. Zouboulis C.C., Jourdan E., Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. J. Eur. Acad. Dermatol. Venereol., 2014, Vol. 28, pp. 527-532.
  65. Zouboulis C.C., Bornstein S.R. Skin and hormones: news from dermato-endocrinology. Dtsch. Med. Wochenschr., 2013, Vol. 138, no. 31-32, pp. 1561-1563.
  66. Zouboulis C.C., Schagen S., Alestas T. The sebocyte culture: a model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhoea and acne. Arch. Dermatol. Res., 2008, Vol. 300, no. 8, pp. 397-413.
  67. Zouboulis C.C. Pathophysiology of acne. What is confirmed? Hautarzt, 2013, Vol. 64, no. 4, pp. 235-240.

Copyright (c) 2020 Rumyantsev A.G., Demina O.M., Raikina E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies